| HOME >> BIOLOGY >> TECHNOLOGY |
Cost of sales increased 1 percent to $590 million in the third quarter of
2008 versus $585 million in the third quarter of 2007. This increase was
due to higher sales volume offset by lower excess inventory write-offs,
lower excess capacity charges and lower cost ENBREL. The Company now
expects full year 2008 adjusted Cost of Sales expense as a percent of
sales to be approximately 15 percent.
Research & Development (R&D) expenses were relatively unchanged at $700
million in the third quarter of 2008 versus $699 million in the third
quarter of 2007. Higher staff-related costs as well as clinical trial
spend for our emerging pipeline were offset by lower clinical trial costs
for our denosumab registrational studies due to completion of enrollment
and the benefit derived from our licensing transaction with Takeda in
Japan. The Company now expects full year 2008 adjusted R&D expense
dollars to be slightly lower than 2007. Consistent with historical
spending patterns, the Company expects an increase in the fourth quarter
versus the third quarter that should be similar in magnitude to the
increase in 2007, though actual results may vary depending on licensing
activities and pipeline progress.
Selling, General & Administrative (SG&A) expenses increased 11 percent to
$890 million in the third quarter of 2008 versus $804 million in the
third quarter of 2007 reflecting higher Wyeth profit share expenses and
staff-related costs offset by lower litigation expense. Wyeth profit
share expenses increased 22 percent to $298 million in the third quarter
of 2008 versus $245 million in the third quarter of 2007. The Company
still expects Wyeth profit share to be one third of adjusted SG&A
expenses for the full year 2008. Excluding Wyeth profit share, adjusted
SG&A ex
'/>"/>
| SOURCE Amgen Copyright©2008 PR Newswire. All rights reserved |